Alterations in genes other than EGFR/ALK/ROS1 in non-small cell lung cancer: trials and treatment options

During the last decade, we have seen tremendous progress in the therapy of lung cancer. Discovery of actionable mutations in EGFR and translocations in ALK and ROS1 have identified subsets of patients with excellent tumor response to oral targeted agents with manageable side effects. In this review,...

Descripción completa

Detalles Bibliográficos
Autores principales: Desai, Arpita, Menon, Smitha P., Dy, Grace K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Chinese Anti-Cancer Association 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4850130/
https://www.ncbi.nlm.nih.gov/pubmed/27144064
http://dx.doi.org/10.28092/j.issn.2095-3941.2016.0008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4850130/
https://www.ncbi.nlm.nih.gov/pubmed/27144064
http://dx.doi.org/10.28092/j.issn.2095-3941.2016.0008

Ejemplares similares